STOCK TITAN

Verastem, Inc. - $VSTM STOCK NEWS

Welcome to our dedicated page for Verastem news (Ticker: $VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.

Verastem, Inc. (NASDAQ: VSTM) is a pioneering biopharmaceutical company dedicated to discovering and developing innovative drugs that target cancer stem cells. These cells are a significant factor in tumor recurrence and metastasis, posing a substantial challenge in the treatment of various cancers. Verastem's mission is to translate groundbreaking cancer stem cell research into new medicines that address major cancers, including breast cancer.

The core focus of Verastem lies in advancing novel anticancer agents, particularly those inhibiting critical signaling pathways that promote cancer cell survival and tumor growth. This includes the development of RAF/MEK inhibitors and FAK inhibitors. These targeted therapies are designed to intercept the mechanisms that allow cancer cells to thrive and spread, offering hope for more effective treatments.

One of the company's notable projects involves the combination of avutometinib (a RAF/MEK clamp) and defactinib (a FAK inhibitor). This drug combination has shown promising results and has been granted breakthrough therapy designation for treating recurrent low-grade serous ovarian cancer (LGSOC), regardless of KRAS status, after one or more prior lines of therapy, including platinum-based chemotherapy.

Verastem has also entered into a strategic partnership with GenFleet Therapeutics, a clinical-stage biotechnology company. This collaboration aims to advance three oncology programs, with GFH375 being the first selected candidate. GFH375, an oral KRAS G12D inhibitor, targets both the

Rhea-AI Summary

Verastem Oncology (Nasdaq: VSTM) has begun a rolling submission of a New Drug Application (NDA) to the FDA for accelerated approval of the avutometinib and defactinib combination. This treatment is aimed at adult patients with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The submission will be completed in the second half of 2024 with mature data from the RAMP 201 trial, which shows promising response rates. Verastem plans to present this data at a medical conference and discuss potential approval paths for KRAS wild-type patients. The company will host an investor call on May 24, 2024, to provide updates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-66.17%
Tags
-
Rhea-AI Summary

Verastem Oncology (Nasdaq: VSTM) announced positive initial interim safety and efficacy results from its ongoing RAMP 205 Phase 1/2 clinical trial for metastatic pancreatic cancer. The trial evaluates avutometinib plus defactinib combined with gemcitabine and Nab-paclitaxel. As of May 14, 2024, in dose level 1, 83% (5/6) of patients achieved a confirmed partial response. One dose-limiting toxicity was observed but later cleared. The results will be presented at the ASCO Annual Meeting on June 1, 2024. Verastem will host a conference call on May 24, 2024, to discuss these findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-66.17%
Tags
none
-
Rhea-AI Summary

Verastem Oncology reported positive business updates, including FDA Fast Track Designations for multiple combination therapies in cancer treatment and plans for upcoming clinical data presentations. Financially, the company ended the first quarter of 2024 with $110.1 million in cash, but reported an increased net loss compared to the same period in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
Rhea-AI Summary

Verastem Oncology (VSTM) will present at the RBC Capital Markets Global Healthcare Conference, demonstrating commitment to advancing cancer treatments. The management team will participate in a fireside chat on May 14, 2024. The webcast can be accessed on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
conferences
-
Rhea-AI Summary
Verastem Oncology appoints Dr. John Hayslip as Chief Medical Officer, bringing extensive oncology expertise to lead clinical programs and advance pipeline assets focused on RAS/MAPK pathway-driven cancers. Dr. Hayslip's appointment follows the departure of Louis J. Denis, M.D. The company aims to submit a rolling NDA for the avutometinib and defactinib combination in low-grade serous ovarian cancer in the first half of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
management
-
Rhea-AI Summary
GenFleet Therapeutics presents promising research findings on GFH375, a potent KRAS G12D inhibitor, at AACR Annual Meeting, with potential for treating KRAS G12D mutant cancers including brain metastases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
Rhea-AI Summary
Verastem Oncology (VSTM) grants stock options to new employees as an inducement material to their employment. The options allow the purchase of 35,000 shares at $11.73 per share, vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
none
-
Rhea-AI Summary
SGO 2024 findings reveal significant concerns among respondents regarding life expectancy, treatment side effects, and emotional well-being.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
none
-
Rhea-AI Summary
Verastem Oncology (VSTM) reports progress in developing combination therapies for cancer, including Phase 3 trials and FDA Fast Track designation. Financial results for Q4 2023 and full year released.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
Rhea-AI Summary
Verastem Oncology (Nasdaq: VSTM) presented multiple oral and poster presentations at the SGO 2024 Annual Meeting on Women’s Cancer. The presentations included a late-breaking oral presentation of avutometinib and defactinib combination data from the RAMP 201 Part A trial in heavily pretreated patients with low-grade serous ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none

FAQ

What does Verastem, Inc. specialize in?

Verastem, Inc. specializes in developing novel drugs that target cancer stem cells to treat various major cancers, including breast cancer.

What are some of Verastem's key projects?

Verastem is working on RAF/MEK and FAK inhibitors to treat cancer. They are also developing a combination therapy of avutometinib and defactinib for low-grade serous ovarian cancer.

Who are Verastem's partners?

One of Verastem's key partners is GenFleet Therapeutics, with whom they are collaborating to advance oncology programs targeting KRAS mutations.

What is GFH375?

GFH375 is an oral KRAS G12D inhibitor being developed in collaboration with GenFleet Therapeutics. It targets cancer cells with KRAS G12D mutations.

What makes Verastem's approach unique?

Verastem focuses on cancer stem cells, aiming to develop therapies that prevent tumor recurrence and metastasis, a major challenge in cancer treatment.

What are RAF/MEK and FAK inhibitors?

RAF/MEK and FAK inhibitors are drugs that target specific signaling pathways in cancer cells, hindering their growth and survival.

What types of cancer is Verastem targeting?

Verastem is targeting major cancers, including breast cancer, ovarian cancer, and those with KRAS mutations.

What recent achievements has Verastem made?

Verastem's combination therapy of avutometinib and defactinib has been granted breakthrough therapy designation for treating recurrent low-grade serous ovarian cancer.

How does Verastem's partnership with GenFleet Therapeutics benefit their research?

The partnership allows Verastem to leverage GenFleet's expertise in oncology to advance new therapies targeting KRAS mutations, enhancing their oncology pipeline.

Where can I find more information about Verastem, Inc.?

More information can be found on their official website: www.verastem.com.

Verastem, Inc.

Nasdaq:VSTM

VSTM Rankings

VSTM Stock Data

87.88M
13.68M
0.55%
66.74%
2.51%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEEDHAM